Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

Amarin reports cash balance of $44 million for first-quarter 2010

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported selected financial results for the fiscal quarter ended March 31, 2010 and provided a progress update of the Company's ANCHOR and MARINE trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.

13 May 2010

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

The U.S. Food and Drug Administration should apply the same rigor to evaluating the science behind claims of foods' and nutritional supplements' health benefits as it devotes to assessing medication and medical technology approvals, says a new report from the Institute of Medicine.

13 May 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug.

13 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

Swedish researchers present a new principle for inhibiting atherosclerosis

7 May 2010

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

BioInvent International AB and ThromboGenics NV announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

6 May 2010

Lack of physical activity and greater TV viewing time associated with wider retinal venules

It is well known that the lack of physical activity is a risk factor for cardiovascular diseases, but what part does it play in retinal vascular caliber? A team of researchers examined the association of physical activity and television viewing time with retinal vascular caliber and explored the differences in white, black, Hispanic and Chinese racial/ethnic groups.

6 May 2010

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defence's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis. By producing a vaccine against the T cell receptors, the researchers have managed to inhibit the development of atherosclerosis in animals.

6 May 2010

Micrus Endovascular reports 24% increase in fourth-quarter neurovascular revenues

Micrus Endovascular Corporation today reported financial results for the three and 12 months ended March 31, 2010 and introduced fiscal 2011 financial guidance.

6 May 2010

GENFIT announces milestone as compound developed in partnership enters the clinic

GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the achievement of a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

New research suggests tPA can act as neuroprotectant against stroke

New research on the properties of the clot-busting stroke drug tPA (tissue-type plasminogen activator) suggests that tPA can act as a neuroprotectant and may form the keystone of an adaptive response to a reduction in blood flow.

6 May 2010

Animal study shows insulin prevents artery damage

Long suspected of worsening artery damage in patients with diabetes, insulin instead protects blood vessels, a new study by Joslin Diabetes Center scientists indicates.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

4 May 2010

JNM supplement examines advances in cardiovascular molecular imaging

The Journal of Nuclear Medicine -the top-rated medical imaging journal worldwide-has published Multimodality Molecular Imaging of the Cardiovascular System, presenting the state of the art of cardiovascular molecular imaging and discussing opportunities and challenges in advancing cardiovascular molecular imaging to clinical practice.

4 May 2010

New data on salt-sensitive hypertension to be presented at ASH 2010 conference

With governmental authorities, academicians, healthcare providers and industry grappling with the level of salt in the diet in an effort to reduce its impact on high blood pressure, new data evaluating a potential genetic component to salt-sensitive hypertension will be presented at the American Society of Hypertension, Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010).

4 May 2010

Natural plant extract could help treat COPD and inflammatory disorders

A widely and safely used plant extract acts as a novel anti-inflammatory agent that may one day be used for the treatment of chronic obstructive pulmonary disease, or COPD, as well as other inflammatory conditions.

4 May 2010

Atherosclerosis News and Research

Further Reading

Amarin reports cash balance of $44 million for first-quarter 2010

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Merck hosts R&D and Business Briefing

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Swedish researchers present a new principle for inhibiting atherosclerosis

Phase II trial: TB-402 demonstrates superior antithrombotic activity to enoxaparin

Lack of physical activity and greater TV viewing time associated with wider retinal venules

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

Micrus Endovascular reports 24% increase in fourth-quarter neurovascular revenues

GENFIT announces milestone as compound developed in partnership enters the clinic

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

New research suggests tPA can act as neuroprotectant against stroke

Animal study shows insulin prevents artery damage

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

JNM supplement examines advances in cardiovascular molecular imaging

New data on salt-sensitive hypertension to be presented at ASH 2010 conference

Natural plant extract could help treat COPD and inflammatory disorders

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News